Does uNTREATED OBSTRUCTIVE SLEEP APNEA hinder RESPONSE TO BEVACIZUMAB IN AGE-RELATED MACULAR DEGENERATION?
Untreated OSA hinders the response of exudative AMD to intravitreal bevacizumab. Treatment of OSA with continuous positive airway pressure therapy yields a subsequent anatomical response and functional improvement while requiring significantly less injections. Identifying and treating underlying OSA earlier in patients with exudative AMD may yield better functional outcomes.
PTX3 may be an important mediator of lung tissue damage associated with mechanical stretch. Determining the production and regulation of PTX3 during mechanical ventilation may be critical in preventing or reducing ventilator-induced lung injury.